MediciNova's MN-166 ALS Study Reaches 50% Enrollment

MediciNova, a biopharmaceutical company, announced that 100 patients have been enrolled in its SEANOBI study, an Expanded-Access Program evaluating Ibudilast for amyotrophic lateral sclerosis (ALS). This represents 50% of the planned 200-patient enrollment across 12 activated sites in the United States. The SEANOBI program is funded by a $22 million grant from the United States===National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS initiative. The program aims to provide Ibudilast access to ALS patients ineligible for randomized clinical trials while collecting real-world biomarker and clinical outcome data. MediciNova is also conducting the COMBAT-ALS Phase 2b/3 trial for Ibudilast with 234 patients in the United States and Canada, with top-line results expected by the end of 2026. Ibudilast has received Orphan Drug Designation from both the United States===Food and Drug Administration (FDA) and the European Union===European Medicines Agency (EMA), and Fast Track Designation from the FDA for ALS treatment.